Antonio Fernández Nebro-rekin lankidetzan egindako argitalpenak (7)

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting

    Reumatologia Clinica, Vol. 18, Núm. 10, pp. 567-573

  3. Hospitalization and Mortality from COVID-19 of Patients with Rheumatic Inflammatory Diseases in Andalusia

    Reumatologia Clinica, Vol. 18, Núm. 7, pp. 422-428

2015

  1. Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the spanish rheumatology society lupus registry (RELESSER) with emphasis on complete versus incomplete lupus differences

    Medicine (United States), Vol. 94, Núm. 1, pp. e267

2014

  1. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis

    Arthritis Research and Therapy, Vol. 16, Núm. 2

  2. The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: Results from a nationwide cohort in Spain (LESIMAB)

    Lupus, Vol. 23, Núm. 10, pp. 1014-1022

2012

  1. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The LESIMAB study

    Lupus, Vol. 21, Núm. 10, pp. 1063-1076